Annals of internal medicine · 2014
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
СтатьяПоддержка NIH: внешняя программаПоддержка правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Shan, Watcha Daena, Holodniy Mark, Goldhaber-Fiebert Jeremy D
Аннотация
BACKGROUND: Prevalence of chronic hepatitis C virus (HCV) infection is high among incarcerated persons in the United States. New, short-duration, high-efficacy therapies may expand treatment eligibility in this population.
OBJECTIVE: To assess the cost-effectiveness of sofosbuvir for HCV treatment in incarcerated populations.
DESIGN: Markov model.
DATA SOURCES: Published literature and expert opinion.
TARGET POPULATION: Treatment-naive men with chronic, genotype 1 HCV monoinfection.
TIME HORIZON: Lifetime.
PERSPECTIVE: Societal.
INTERVENTION: No treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir. For inmates with short remaining sentences (<1.5 years), only no treatment or sofosbuvir 3-drug therapy was feasible; for those with long sentences (≥1.5 years; mean, 10 years), all strategies were considered. After release, eligible persons could receive sofosbuvir 3-drug therapy.
OUTCOME MEASURES: Discounted costs (in 2013 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.
RESULTS OF BASE-CASE ANALYSIS: The strategies yielded 13.12, 13.57, 14.43, and 15.18 QALYs, respectively, for persons with long sentences. Sofosbuvir produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcinoma (9%), resulting in 2.1 additional QALYs at an added cost exceeding $54,000 compared with no treatment. For persons with short sentences, sofosbuvir cost $25,700 per QALY gained compared with no treatment; for those with long sentences, it dominated other treatments, costing $28,800 per QALY gained compared with no treatment.
RESULTS OF SENSITIVITY ANALYSIS: High reinfection rates in prison attenuated cost-effectiveness for persons with long sentences.
LIMITATIONS: Data on sofosbuvir's long-term effectiveness and price are limited. The analysis did not consider women, Hispanic persons, or patients co-infected with HIV or hepatitis B virus.
CONCLUSION: Sofosbuvir-based treatment is cost-effective for incarcerated persons, but affordability is an important consideration.
PRIMARY FUNDING SOURCE: National Institutes of Health.
OBJECTIVE: To assess the cost-effectiveness of sofosbuvir for HCV treatment in incarcerated populations.
DESIGN: Markov model.
DATA SOURCES: Published literature and expert opinion.
TARGET POPULATION: Treatment-naive men with chronic, genotype 1 HCV monoinfection.
TIME HORIZON: Lifetime.
PERSPECTIVE: Societal.
INTERVENTION: No treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir. For inmates with short remaining sentences (<1.5 years), only no treatment or sofosbuvir 3-drug therapy was feasible; for those with long sentences (≥1.5 years; mean, 10 years), all strategies were considered. After release, eligible persons could receive sofosbuvir 3-drug therapy.
OUTCOME MEASURES: Discounted costs (in 2013 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.
RESULTS OF BASE-CASE ANALYSIS: The strategies yielded 13.12, 13.57, 14.43, and 15.18 QALYs, respectively, for persons with long sentences. Sofosbuvir produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcinoma (9%), resulting in 2.1 additional QALYs at an added cost exceeding $54,000 compared with no treatment. For persons with short sentences, sofosbuvir cost $25,700 per QALY gained compared with no treatment; for those with long sentences, it dominated other treatments, costing $28,800 per QALY gained compared with no treatment.
RESULTS OF SENSITIVITY ANALYSIS: High reinfection rates in prison attenuated cost-effectiveness for persons with long sentences.
LIMITATIONS: Data on sofosbuvir's long-term effectiveness and price are limited. The analysis did not consider women, Hispanic persons, or patients co-infected with HIV or hepatitis B virus.
CONCLUSION: Sofosbuvir-based treatment is cost-effective for incarcerated persons, but affordability is an important consideration.
PRIMARY FUNDING SOURCE: National Institutes of Health.